Oncolytics Biotech Inc T.ONC

New Press Release - Oncolytics Biotech® Announces Upcoming Presentations at the American Society of Clinical Oncology Annual Meeting

SAN DIEGO and CALGARY, AB, April 25, 2024 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, today announced the acceptance of two abstracts at the 2024 American Society of Clinical Oncology (ASCO...read article.

[Azzak34]

https://www.cancer.gov/news-events/cancer-currents-blog/2023/oncolytic-virus-blocking-tgf-beta A major rate-limiting factor with oncolytic virus continues to be the need to inject them directly into tumors, Dr. Gulley said. Injection is relatively easy for cancers in the skin, such as melanoma, he continued, but it's much more difficult for tumors located deeper in the body.  So to

[Lesalpes29]

Positive NR. We are still in the game! Will add a few more today. This year as to be the YEAR where we all long shareholders are going to be rewarded. Roche is watching us closely! GL 

[Noteable]

CD8+ TiL cells are critical mediators of cytotoxic effector function in cancer, however, in cancer, CD8+ TiL cells undergo a progressive loss of cytokine production and cytotoxicity, a state termed T-cell exhaustion as well as T-cell dysfuntion, resulting in a failure of T-cells to eradicate tumor cells in the tumor microenvironment (TME). Also, high levels of PD-1 expression contribute

[spesestsemper]

so - these are the two things that come up with those abstract numbers in an asco publication ExoLuminate: An observational registry study for detection of pancreatic adenocarcinoma (PDAC) in high-risk or clinically suspicious patients. | Journal of Clinical Oncology (ascopubs.org) A phase I/II trial of gemcitabine and S-1 therapy in patients with resected pancreatic cancer: Japanese Study Group